Clinical Trial Update: Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating Velcade (bortezomib) and lenalidomide in patients with relapsed myelodysplastic syndrome or acute myeloid leukemia after allogeneic s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Lenalidomide (lenalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED